

<p>Informazione Regolamentata n. 20106-8-2025</p>	<p>Data/Ora Inizio Diffusione 17 Marzo 2025 13:28:10</p>	<p>Euronext Star Milan</p>
---	--	----------------------------

Societa' : PHARMANUTRA

Identificativo Informazione Regolamentata : 202514

Utenza - Referente : PHARMANUTRAN04 - Roberto Lacorte

Tipologia : 1.1

Data/Ora Ricezione : 17 Marzo 2025 13:28:10

Data/Ora Inizio Diffusione : 17 Marzo 2025 13:28:10

Oggetto : Pharmanutra || PR clarification and integration note

*Testo del comunicato*

Vedi allegato

**PHARMANUTRA S.P.A.**  
**CLARIFICATION NOTE ON THE PRESS RELEASE OF 14 MARCH 2025**  
**WITH RESPECT TO THE BUSINESS OUTLOOK**

*Pisa, 17 March 2025* - To supplement and clarify what was reported in the [press release](#) of Friday, 14 March in the third paragraph of the section 'Business Outlook', **PharmaNutra S.p.A. (MTA; Ticker PHN)** specifies that there are no specific critical issues that may arise from 'the unpredictable developments of scenarios related to the current geopolitical situation that generate a generalised macroeconomic uncertainty' that may affect the achievement of the company's objectives. In particular, no significant impact is expected from the possible introduction of customs duties on Group products destined for the American market.

**PharmaNutra S.p.A.**

*Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it can claim important Sucrosomial® Technology patents, and is considered one of the top players in the sector of medical devices dedicated to the restoration of joint capacity thanks to the Cetilar® brand, now on the market also with Cetilar® Nutrition, a line of supplements designed for those who practice sport constantly. Over the years the Group - present abroad in over 89 countries - has developed precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.*

[PharmaNutra.it](http://PharmaNutra.it)

*For further information:*

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa  
 Tel. +39 050 7846500  
[investorrelation@pharmanutra.it](mailto:investorrelation@pharmanutra.it)

Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan  
 Tel. +39 02 83635708

Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
 Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

